Let’s dig into the relative performance of Cigna (NYSE:CI) and its peers as we unravel the now-completed Q4 health insurance ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Cigna looks undervalued at under 10x earnings, with strong growth potential. Evernorth continues to expand, adding to the company’s long-term value. Large stock buybacks are supporting earnings ...

Progyny Inc (PGNY) reports strong financial performance with record ART cycles and strategic expansions, despite challenges ...

All but Cigna were among the portfolio's top-10 holdings ... We avoided these benchmark components in Q4, as we did not see compelling value opportunities among these names. Throughout the quarter ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the health insurance providers industry, including Molina Healthcare (NYSE:MOH) and ...

Cigna's fourth-quarter results were impacted ... which measures medical costs as a percentage of premiums, rose to 87.9% in Q4 from 82.2% a year earlier. "While higher medical costs in our stop ...

Cigna reported fourth-quarter 2024 adjusted earnings per share of $6.64, which missed the Zacks Consensus Estimate by 15.2% due to a decline in its overall medical customer base and elevated ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the health insurance providers stocks, including Progyny (NASDAQ:PGNY) and its peers. Upfront premiums collected by health ...

Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system, ...

A majority of small- and mid-sized businesses (62%) say they're taking a hit due to the ongoing U.S.-Canada trade war, finds data from the Canadian Federation of Independent Business (CFIB)'s upcoming ...